Merieux buys control of India's Shantha

France's Merieux Alliance has acquired a majority stake in India's Shantha Biotechnics. The deal gives Merieux a new development center for vaccines, therapeutic proteins and monoclonal antibodies. Shantha earned $20 million in revenue last year, making it India's fourteenth largest biotech company. Merieux sees the deal as a direct way to develop a beachhead in the Indian drug market.

"The stake will help us strengthen our presence within the country, which has strong potential in the field of biology and significant needs in public health," said Rekha Khanna, managing director of Merieux Alliance India.

- read this report on the deal from Red Herring

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.